Tag - Kura

Developments

Kura reports compelling data from trial of FTI in solid tumors

Kura Oncology (NASDAQ: KURA) has reported compelling first-in-human data from the FIT-001 clinical trial of its next-generation farnesyl transferase inhibitor (FTI) darlifarnib in combination with adagrasib in heavily...

May 26, 2026

Developments

Kura Oncology gets second fast track designation for tipifarnib

The FDA granted fast track designation to Kura Oncology’s (NASDAQ:KURA) tipifarnib for the treatment of adult patients with relapsed or refractory angioimmunoblastic T-cell lymphoma, follicular T-cell lymphoma and nodal...

March 3, 2020

Tag - Kura

Kura reports compelling data from trial of FTI in solid tumors

Kura Oncology gets second fast track designation for tipifarnib

Subscribe